Orion raises outlook after prostate cancer drug deal with Bayer

June 2, 2014 6:53 AM

16 0

HELSINKI: Finnish drug makerOrion said on Monday it had struck a deal with German peer Bayer to develop a prostate cancer drug, with the deal allowing Orion to upgrade its full-year sales and profit outlook.

The two companies will this year start a clinical phase III trial of the drug, called ODM-201, in patients with non-metastatic prostate cancer that cannot be treated by standard hormone therapy, Orion said in a statement.

Read more

To category page